These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 15866630

  • 21. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a single center experience.
    Donauer J, Wilpert J, Geyer M, Schwertfeger E, Kirste G, Drognitz O, Walz G, Pisarski P.
    Xenotransplantation; 2006 Mar; 13(2):108-10. PubMed ID: 16623802
    [Abstract] [Full Text] [Related]

  • 22. [Daclizumab in combination with mycophenolate mofetil and a late introduction of Tacrolimus at low doses, as a therapeutic approach in the elderly renal transplant donor-recipients pairs in kidney transplant].
    Gentil MA, Osuna A, Capdevilla L, Cantarell C, Pereira P, Mazuecos A, González Molina M.
    Nefrologia; 2008 Mar; 28(3):287-92. PubMed ID: 18590495
    [Abstract] [Full Text] [Related]

  • 23. Rituximab induction therapy in highly sensitized kidney transplant recipients.
    Yin H, Wan H, Hu XP, Li XB, Wang W, Liu H, Ren L, Zhang XD.
    Chin Med J (Engl); 2011 Jul 05; 124(13):1928-32. PubMed ID: 22088448
    [Abstract] [Full Text] [Related]

  • 24. Pediatric liver transplantation with daclizumab induction.
    Heffron TG, Pillen T, Smallwood GA, Welch D, Oakley B, Romero R.
    Transplantation; 2003 Jun 27; 75(12):2040-3. PubMed ID: 12829908
    [Abstract] [Full Text] [Related]

  • 25. Kidney transplantation from living donors: comparison of results between related and unrelated donor transplants under new immunosuppressive protocols.
    Chkhotua AB, Klein T, Shabtai EL, Yussim A, Bar-Nathan N, Shaharabani E, Lustig S, Mor E.
    Isr Med Assoc J; 2003 Sep 27; 5(9):622-5. PubMed ID: 14509149
    [Abstract] [Full Text] [Related]

  • 26. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.
    Cuppoletti A, Perez-Villa F, Vallejos I, Roig E.
    Transplant Proc; 2005 Nov 27; 37(9):4036-8. PubMed ID: 16386620
    [Abstract] [Full Text] [Related]

  • 27. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.
    Chen JS, Li LS, Cheng DR, Ji SM, Sun QQ, Cheng Z, Wen JQ, Sha GZ, Liu ZH.
    Transplant Proc; 2009 Jun 27; 41(5):1557-61. PubMed ID: 19545678
    [Abstract] [Full Text] [Related]

  • 28. Outcome of 3 years of immunosuppression with tacrolimus in more than 1,000 renal transplant recipients in japan.
    Sonoda T, Takahara S, Takahashi K, Uchida K, Ohshima S, Toma H, Tanabe K, Yoshimura N, Japanese Tacrolimus Study Group.
    Transplantation; 2003 Jan 27; 75(2):199-204. PubMed ID: 12548123
    [Abstract] [Full Text] [Related]

  • 29. ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment.
    Nordén G, Briggs D, Cockwell P, Lipkin G, Mjörnstedt L, Mölne J, Ready A, Rydberg L, Samuelsson O, Svalander CT, Breimer ME.
    Xenotransplantation; 2006 Mar 27; 13(2):148-53. PubMed ID: 16623810
    [Abstract] [Full Text] [Related]

  • 30. Calcineurin inhibitor-free immunosuppressive strategy in elderly recipients of renal allografts from deceased donors: 1-year results from a prospective single center trial.
    Arbogast HP, Hoffmann JN, Illner WD, Hillebrand GF, Fischereder M, Jauch KW, Land W.
    Transplant Proc; 2009 Mar 27; 41(6):2529-32. PubMed ID: 19715968
    [Abstract] [Full Text] [Related]

  • 31. Outcomes of kidney transplants from non-heart-beating deceased donors as reported to the Japan Organ Transplant Network from April 1995-December 2003: a multi-center report.
    Teraoka S, Nomoto K, Kikuchi K, Hirano T, Satomi S, Hasegawa A, Uchida K, Akiyama T, Tanaka S, Babazona T, Shindo K, Nakamura N.
    Clin Transpl; 2004 Mar 27; ():91-102. PubMed ID: 16704141
    [Abstract] [Full Text] [Related]

  • 32. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
    Kandus A, Grego K, Bren AF.
    Ther Apher Dial; 2005 Jun 27; 9(3):262-4. PubMed ID: 15967003
    [Abstract] [Full Text] [Related]

  • 33. A prospective 3-yr evaluation of tacrolimus-based immunosuppressive therapy in immunological high risk renal allograft recipients.
    Zaltzman JS, Boucher A, Busque S, Halloran PF, Landsberg DN, McAlister VC, Russell D, Shoker A, Shapiro J, Tchervenkov JI, Ferguson R.
    Clin Transplant; 2005 Feb 27; 19(1):26-32. PubMed ID: 15659130
    [Abstract] [Full Text] [Related]

  • 34. Anti-CD25 monoclonal antibody sequential immunosuppressive induction therapy in renal transplants with high risk of delayed graft function.
    González E, Gutiérrez E, Hernández Y, Roselló G, Gutiérrez MJ, Martínez EG, Manzanera MJ, García JA, Praga M, Morales JM, Andrés A.
    Transplant Proc; 2005 Nov 27; 37(9):3736-7. PubMed ID: 16386522
    [Abstract] [Full Text] [Related]

  • 35. A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience.
    Ji SM, Li LS, Cheng Z, Cheng DR, Sun QQ, Chen JS, Sha GZ, Liu ZH.
    Transplant Proc; 2007 Jun 27; 39(5):1396-401. PubMed ID: 17580147
    [Abstract] [Full Text] [Related]

  • 36. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
    Sánchez-Fructuoso AI, Prats D, Marques M, Ridao N, Conesa J, García Mena M, Torrente J, Barrientos A.
    Transplant Proc; 2003 Aug 27; 35(5):1689-90. PubMed ID: 12962759
    [Abstract] [Full Text] [Related]

  • 37. Clinicopathologic evaluation of short-term outcome after early corticosteroid discontinuation in kidney transplantation.
    Miura M, Ogawa Y, Kubota KC, Harada H, Shimoda N, Seki T, Hirano T, Nonomura K.
    Clin Transplant; 2009 Aug 27; 23 Suppl 20():10-6. PubMed ID: 19594589
    [Abstract] [Full Text] [Related]

  • 38. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
    Demirbaş A, Tuncer M, Yavuz A, Gürkan A, Kaçar S, Cetinkaya R, Tekin S, Akbaş SH, Akaydin M, Ersoy F, Yakupoğlu G.
    Transplant Proc; 2004 Aug 27; 36(1):175-7. PubMed ID: 15013338
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.
    Baez Y, Giron F, Niño-Murcia A, Rodríguez J, Salcedo S.
    Transplant Proc; 2008 Apr 27; 40(3):697-9. PubMed ID: 18454990
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.